Dishman Carbogen Amcis reported its un-audited financial results for the quarter ended June 30, 2026 (Q1 FY27). Net revenue stood at ₹6,776 million, a decrease of 4.29% year-over-year, primarily due to a deferment in CDMO revenue. EBITDA margin also narrowed significantly to 8.9% from 19.9% in Q1 FY26.
Q1 FY27 Financial Highlights
Dishman Carbogen Amcis has released its un-audited financial results for the first quarter of the financial year 2027 (Q1 FY27), ending on June 30, 2026. The company reported a net revenue of ₹6,776 million, representing a decrease of 4.29% compared to ₹7,080 million in Q1 FY26. This decline was attributed mainly to the deferment of CDMO revenue, although growth in the Marketable Molecules (MM) segment partially offset the impact.
Segment Performance
CDMO revenue saw a year-over-year decline of 12.6%, largely due to customer-requested rescheduling of project deliverables valued at approximately CHF 10 million. In contrast, revenue from the Marketable Molecules segment experienced a significant increase of 48% in Q1 FY27, driven by higher Cholesterol revenue.
EBITDA and Margins
The EBITDA margin for Q1 FY27 stood at 8.9%, a considerable reduction from 19.9% in Q1 FY26. The CDMO segment margin declined to 6.3% from 17.9% in the prior year quarter, impacted by deferred revenues and a largely fixed cost base. An additional factor affecting margins was a notional foreign exchange loss of INR 117.3 million. The MM segment margin also saw a decrease to 18.6% from 32.4% in Q1 FY26, attributed to higher sales of Cholesterol compared to Vitamin D Analogues. However, these MM segment margins are noted to be in line with the full year FY26 margins.
Capital Expenditure and Debt
The company reported an addition in Capex during Q1 FY27 amounting to CHF 4.9 million. As of June 30, 2026, the net debt, excluding lease liabilities, was CHF 153.6 million, compared to CHF 146.8 million as of March 31, 2026.
Source: BSE
